Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro.

Animals Antineoplastic Agents / pharmacology Bone Neoplasms / drug therapy Cell Culture Techniques / methods Cell Proliferation / drug effects Docetaxel / pharmacology Drug Screening Assays, Antitumor / methods Humans Male Mice, SCID PC-3 Cells Prostatic Neoplasms / drug therapy Radium / pharmacology Spheroids, Cellular / drug effects Tumor Cells, Cultured / drug effects Tumor Microenvironment / drug effects
3D culture Bone metastasis In vitro engineered bone microenvironment Microscopy Prostate cancer Therapy response

Journal

Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316

Informations de publication

Date de publication:
03 2019
Historique:
received: 20 06 2018
revised: 24 12 2018
accepted: 20 01 2019
pubmed: 27 1 2019
medline: 22 5 2020
entrez: 26 1 2019
Statut: ppublish

Résumé

Mechanistic analysis of metastatic prostate cancer (PCa) biology and therapy response critically depends upon clinically relevant three-dimensional (3D) bone-like, organotypic culture. We here combine an engineered bone-mimetic environment (BME) with longitudinal microscopy to test the growth and therapy response of 3D PCa tumoroids. Besides promoting both tumor-cell autonomous and microenvironment-dependent growth in PCa cell lines and patient-derived xenograft cells, the BME enables in vivo-like tumor cell response to therapy, and reveals bone stroma dependent resistance to chemotherapy and BME-targeted localization and induction of cytoxicity by Radium-223. The BME platform will allow the propagation, compound screening and mechanistic dissection of patient-derived bone tumor isolates and applications toward personalized medicine.

Identifiants

DOI: 10.1016/j.biomaterials.2019.01.027 PMID: 30682644 PMC: PMC7094882
pubmed: 30682644
pii: S0142-9612(19)30046-8
doi: 10.1016/j.biomaterials.2019.01.027
pmc: PMC7094882
mid: NIHMS1565422
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Docetaxel 15H5577CQD
Radium-223 8BR2SOL3L1
Radium W90AYD6R3Q

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

296-304

Subventions

Organisme : European Research Council
ID : 617430
Pays : International
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA210184
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Oncotarget. 2017 Aug 24;8(43):74987-75006
pubmed: 29088840
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s
pubmed: 17062709
Cancer Res. 1994 May 15;54(10):2577-81
pubmed: 8168083
Cancer Res. 2014 Feb 15;74(4):1272-83
pubmed: 24356420
J Bone Miner Res. 2014 Apr;29(4):878-91
pubmed: 24115222
Nat Rev Drug Discov. 2013 Mar;12(3):217-28
pubmed: 23449307
Cancer Cell. 2017 Dec 11;32(6):731-747.e6
pubmed: 29232552
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):214-9
pubmed: 25524628
Invest Urol. 1979 Jul;17(1):16-23
pubmed: 447482
Nat Methods. 2007 Oct;4(10):855-60
pubmed: 17767164
Nat Biomed Eng. 2016;1:
pubmed: 28979821
Nat Protoc. 2017 Apr;12(4):639-663
pubmed: 28253234
Cancer Res. 2008 Dec 1;68(23):9996-10003
pubmed: 19047182
Cold Spring Harb Perspect Med. 2018 Aug 1;8(8):
pubmed: 29311126
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Biomaterials. 2016 Jan;77:164-72
pubmed: 26599623
Trends Biotechnol. 2018 Mar;36(3):242-251
pubmed: 29310843
Nat Rev Cancer. 2016 May 25;16(6):373-86
pubmed: 27220481
J Clin Invest. 2008 Aug;118(8):2697-710
pubmed: 18618013
J Vasc Interv Radiol. 2018 Jun;29(6):880-882.e1
pubmed: 29798759
J Pharm Sci. 2011 Jan;100(1):59-74
pubmed: 20533556
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
Biomaterials. 2015 Oct;66:53-66
pubmed: 26196533
Biomaterials. 2012 Feb;33(4):1065-78
pubmed: 22071100
Biomaterials. 2010 Nov;31(31):7960-70
pubmed: 20688388
J Biol Methods. 2015;2(1):
pubmed: 26146646
Neoplasia. 2010 Feb;12(2):116-27
pubmed: 20126470
Cancer Res. 2013 Sep 1;73(17):5315-9
pubmed: 23733750
ACS Appl Mater Interfaces. 2015 Feb 4;7(4):2269-79
pubmed: 25557227
Biomaterials. 2014 Mar;35(8):2454-61
pubmed: 24388382
Oncotarget. 2016 Jul 12;7(28):44803-44820
pubmed: 27027241
Sci Transl Med. 2011 Nov 30;3(111):111ra121
pubmed: 22133722
Biomed Res Int. 2016;2016:9750795
pubmed: 27294148
Lancet Oncol. 2005 Apr;6(4):229-39
pubmed: 15811618
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
J Tissue Eng Regen Med. 2018 Jan;12(1):e473-e485
pubmed: 27599449
J Natl Cancer Inst. 2013 Jun 19;105(12):908-16
pubmed: 23682134
J Clin Invest. 2011 Apr;121(4):1298-312
pubmed: 21436587
Adv Drug Deliv Rev. 2014 Dec 15;79-80:214-21
pubmed: 24816064
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Natl Cancer Inst. 2015 Dec 18;108(5):
pubmed: 26683407
Bone. 2014 Jun;63:121-31
pubmed: 24530694

Auteurs

Claudia Paindelli (C)

David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA; Radboud University Nijmegen, Nijmegen, Geert Grooteplein 26, 6500 HB Nijmegen, the Netherlands.

Nora Navone (N)

David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA.

Christopher J Logothetis (CJ)

David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA.

Peter Friedl (P)

David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA; Radboud University Nijmegen, Nijmegen, Geert Grooteplein 26, 6500 HB Nijmegen, the Netherlands; Cancer Genomics Centre (CGC.nl), 3584 Utrecht, the Netherlands.

Eleonora Dondossola (E)

David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA. Electronic address: EDondossola@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Maladies ostéomusculaires › Maladies osseuses › Tumeurs osseuses › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Techniques de culture › Techniques de culture cellulaire › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Docetaxel › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de criblage d'agents antitumoraux › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris SCID › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules PC-3 › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Radium › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Cellules › Cellules cultivées › Sphéroïdes de cellules › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Engineered bone for probing organotypic growth...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Engineered bone for probing organotypic growth...